Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini P G, Liuzzi A
J Endocrinol Invest. 1983 Feb;6(1):47-50. doi: 10.1007/BF03350560.
We report two cases with macroprolactinoma who during medical treatment with bromocriptine showed a normalization of PRL levels and a reduction of tumor size as documented by computed tomography. After a few months of therapy both patients suddenly complained of worsening of their visual fields and a computed tomography demonstrated a reenlargement of the tumor mass; whereas in one patient PRL levels remained always within normal range, in the other patient, who was taking spiramycin for an intercurrent illness, there was also an escape of the hormonal secretion from the inhibitory effect of bromocriptine. The first patient underwent surgery, whereas in the second patient continuation of bromocriptine and interruption of antibiotic treatment resulted in progressive improvement in visual fields and a reduction of tumor size again. We want to stress that in patients with macroprolactinomas responsive to the medical treatment both in terms of PRL secretion and of tumor size reduction, an escape from the effects of bromocriptine, although infrequently, may occur.
我们报告了两例大泌乳素瘤患者,在接受溴隐亭药物治疗期间,催乳素(PRL)水平恢复正常,计算机断层扫描显示肿瘤大小缩小。经过几个月的治疗,两名患者突然抱怨视野恶化,计算机断层扫描显示肿瘤块再次增大;其中一名患者的PRL水平始终保持在正常范围内,而另一名因并发疾病正在服用螺旋霉素的患者,其激素分泌也摆脱了溴隐亭的抑制作用。第一名患者接受了手术,而第二名患者继续使用溴隐亭并中断抗生素治疗后,视野逐渐改善,肿瘤大小再次缩小。我们想强调的是,对于大泌乳素瘤患者,无论是在PRL分泌还是肿瘤大小缩小方面对药物治疗有反应的,溴隐亭的作用偶尔可能会失效。